Ignite Creation Date:
2024-05-05 @ 5:18 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00420680
Status:
COMPLETED
Last Update Posted:
2017-08-22
First Post:
2007-01-10
Brief Title:
Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients 194309P05934
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Multi -Center Randomized Parallel-Group Placebo-Controlled Safety Assessor-Blinded Trial Evaluating the Safety and Efficacy of Sugammadex in Cardiac Patients
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety of 20 mgkg and 40 mgkg sugammadex given as a reversal agent at reappearance of T2 after 06 mgkg rocuronium in cardiac patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 194309 | None | None | None |
| EudraCT Number 2005-002000-42 | None | None | None |